Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.

被引：0
|
作者：
Engel-Nitz, Nicole M.
Becker, Laura
Gerdes, Randall
Hao, Yanni
机构：
[1] Optum, Eden Prairie, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2-Metastatic Breast Cancer
    Brufsky, Adam M.
    Sandin, Rickard
    Stergiopoulos, Stella
    Chen, Connie
    Karanth, Siddharth
    Li, Benjamin
    Esterberg, Elizabeth
    Makari, Doris
    Candrilli, Sean D.
    Goyal, Ravi K.
    Rugo, Hope S.
    CANCER MEDICINE, 2025, 14 (07):
  • [42] Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer
    Fitzgerald, D. M.
    Henderson, L. E.
    Isakoff, S. J.
    Moy, B.
    Oh, K.
    Shih, H. A.
    Dias-Santagata, D.
    Borger, D. R.
    Iafrate, A. J.
    Brastianos, P. K.
    Bardia, A.
    Juric, D.
    CANCER RESEARCH, 2017, 77
  • [43] Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2-metastatic breast cancer patients in the United States
    Mougalian, S. S.
    Zhang, J.
    Kish, J. K.
    Zettler, M. E.
    Feinberg, B. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S72 - S72
  • [44] Observational study of HR+/HER2-metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
    Blanch, Salvador
    Gil-Gil, Juan Miguel
    Arumi, Miriam
    Aguirre, Elena
    Segui, Miguel Angel
    Atienza, Manuel
    Diaz-Cerezo, Silvia
    Molero, Alberto
    Cervera, Jose Manuel
    Gavila, Joaquin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2950 - 2959
  • [45] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
    Waks, A. G.
    Gharaibeh, M.
    Sjekloca, N.
    Poluparthi, N.
    Shah, A.
    Bergamaco, E.
    MacCannell, T.
    Leung, G.
    Ntalla, I.
    Oko-osi, H.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
  • [46] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [48] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [49] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S11 - S12
  • [50] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
12345